Literature DB >> 9403280

Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature.

J P Ottervanger1, J H Wilson, B H Stricker.   

Abstract

OBJECTIVES: To analyse reports of drug-induced myocardial infarction and chest pain sent to a national reporting centre. To review which drugs were suspected of exhibiting these adverse events and what mechanisms were involved.
METHODS: During the 20-year period 1975 through 1994, a total of 19,141 reports on adverse reactions to drugs were received by the Netherlands Centre for Monitoring of Adverse Reactions to Drugs. Of these 19,141 reports, 220 (1.1%) were concerned with drug-induced chest pain or myocardial infarction. After excluding reports in which the causal relationship was unlikely, poorly documented reports and reports on cases of overdosage, 183 reports (84%) were analysed.
RESULTS: There were 130 reports (71%) of drug-induced chest pain and 53 reports (29%) of drug-induced myocardial infarction. A total of 104 reports concerned females (57%). The most frequently reported suspected drugs were the antimigraine drug sumatriptan (33 reports, 4 concerning myocardial infarction), the calcium antagonist nifedipin (9 reports, 2 of myocardial infarction) and nicotine [9 reports (8 patches, 1 chewing gum), 5 concerning myocardial infarction]. There were 18 reports of a fatal outcome.
CONCLUSIONS: Several drugs can produce chest pain or myocardial ischaemia. It is important to recognise drugs as a potential cause, especially in patients with normal coronary arteries.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403280     DOI: 10.1007/s002280050346

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery.

Authors:  I Bouchelet; B Case; A Olivier; E Hamel
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

2.  Atrial fibrillation associated with sumatriptan.

Authors:  D R Morgan; M Trimble; G E McVeigh
Journal:  BMJ       Date:  2000-07-29

3.  Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).

Authors:  Manfred Hauben; Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

4.  Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries.

Authors:  Christopher M H Newman; Ian Starkey; Nigel Buller; Ricardo Seabra-Gomes; Simon Kirby; Jayasena Hettiarachchi; David Cumberland; William S Hillis
Journal:  Eur J Clin Pharmacol       Date:  2005-09-08       Impact factor: 2.953

5.  Acute Chest Pain as an Infusion Reaction to Vedolizumab.

Authors:  Asaf Levartovsky; Miri Yavzori; Ella Fudim; Uri Kopylov; Shomron Ben-Horin; Bella Ungar
Journal:  Case Rep Gastroenterol       Date:  2022-06-28

6.  Initial Abortive Treatments for Migraine Headache.

Authors:  Sylvia Lucas
Journal:  Curr Treat Options Neurol       Date:  2002-09       Impact factor: 3.598

Review 7.  Tolerability of the triptans: clinical implications.

Authors:  Giuseppe Nappi; Giorgio Sandrini; Grazia Sances
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  A novel effect of Noscapine on patients with massive ischemic stroke: A pseudo-randomized clinical trial.

Authors:  Massoud Mahmoudian; Mohammad Rezvani; Mohammad Rohani; Foozya Benaissa; Mehdi Jalili; Shadi Ghourchian
Journal:  Iran J Neurol       Date:  2015-01-05

9.  Vasospasm induced myocardial ischaemia secondary to sumatriptan use.

Authors:  Kenneth Okonkwo; Utkarsh Ojha
Journal:  BMJ Case Rep       Date:  2020-08-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.